Fig. 2
From: Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
Mean baseline PJPS for selected joint pairs in ORAL Start (patients receiving tofacitinib 5 mg BID). Patients were receiving tofacitinib 5 mg BID; data represent the mean baseline PJPS in component joint pairs of the 68/66-joint count in patients with PJPS > 0 at baseline. The total number of patients assessed at baseline was N = 373. Refer to Table 1 for the number and proportion of patients with specific joint involvement at baseline. BID, twice daily; N, number of patients assessed; PJPS, paired joint pathology score